Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Hinde Group Marc Werres | “Our positions in Becton, Dickinson and Company common stock (NYSE: BDX) made notable positive contributions. The return from our position in BDX benefited from the completion of Becton Dickinson's Rev” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
BA Beutel Goodman U.S. Value Fund Glenn Fortin and Rui Cardoso | “Becton Dickinson offers an attractive recurring revenue stream and leadership across diverse medical categories. Having waited out product-specific and global macro headwinds, the manager is constructive on the company's renewed commercial execution focus.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Aristotle Core Equity Fund Mr. Fitzpatrick | “Becton Dickinson detracted from relative performance in the second quarter following a worse-than-expected fiscal quarter earnings report in which the company felt the impact of cuts to the National Institutes of Health (NIH) budget and uncertainty around future cuts. Furthermore, forward earnings and revenue guidance were reduced to reflect the continued weakness in funding for biosciences R&D and the expected impact of tariffs. BSD Analysis: BD is the industrial-strength circulatory system of global healthcare — syringes, infusion sets, diagnostics, and lab automation that hospitals cannot function without. It's a scale-driven consumables machine with a growing portfolio of higher-tech offerings, from drug-delivery platforms to advanced molecular diagnostics. After years of integration cleanup, BD finally has a simpler, more profitable operating model, and the steady uptick in elective procedures is flowing straight into earnings. With recurring consumables as its backbone and innovation seeding new growth, BD is one of the medtech names with the lowest downside and surprising operating leverage on the upside. The market still treats it like a plodder — but BD is steadily upgrading itself.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Aristotle Atlantic Core Equity Strategy Mr. Fitzpatrick | “Becton Dickinson detracted from relative performance in the second quarter following a worse-than-expected fiscal quarter earnings report in which the company felt the impact of cuts to the National Institutes of Health (NIH) budget and uncertainty around future cuts. Furthermore, forward earnings and revenue guidance were reduced to reflect the continued weakness in funding for biosciences R&D and the expected impact of tariffs. BSD Analysis: BD sits in the “too important to cut” bucket of hospital spending — syringes, catheters, diagnostics, infusion pumps, and lab systems that are embedded in standard of care globally. After years of integration work, the portfolio is now streamlined enough that operating leverage is starting to show through. Procedure volumes are normalizing, infection-prevention spend is structurally higher, and BD's recurring consumables base makes revenue highly predictable. The company is also leaning into higher-tech growth adjacencies like molecular diagnostics and advanced drug delivery. Debt is manageable, innovation is picking up, and management is clearly more focused on margins than empire-building. This is a medtech workhorse that throws off steady compounder returns.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
First Eagle Global Fund First Eagle Investment Management, LLC | “Becton Dickinson develops and manufactures medical devices, instrument systems and reagents used in a variety of professional and public settings. The company reported lower-than-expected revenue for its most recent quarter because of weakness in its research instrument and diagnostics businesses resulting from lower global research spending and the impact of tariffs. We continue to like Becton Dickinson's ability to generate cash and its commitment to enhancing shareholder value through stock buybacks and dividends. BSD Analysis: Despite a softer quarter in certain research and diagnostics lines, BD's latest fiscal year showed revenue growth of roughly 8% and high single-digit adjusted EPS growth, underscoring the resilience of its diversified portfolio. Gross margin expansion driven by productivity initiatives indicates underlying pricing power and cost control. The company has returned over $2 billion to shareholders recently via dividends and repurchases, while maintaining investment in innovation across injection systems, infusion therapy and diagnostics. At a mid-20s P/E multiple, BD is not cheap, but offers a high-quality, cash-generative exposure to secular healthcare demand with some cyclical upside as research spending normalizes. Tariff headwinds appear manageable relative to the breadth of the franchise.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
